These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38115271)

  • 1. The effect of close and intensive therapeutic monitoring of patients with poorly controlled type 2 diabetes with different glycemic background.
    Erbakan AN; Arslan Bahadir M; Kaya FN; Güleç B; Vural Keskinler M; Faydaliel Ö; Mesçi B; Oğuz A
    Medicine (Baltimore); 2023 Dec; 102(50):e36680. PubMed ID: 38115271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic memory: Evolving concepts.
    Misra A; Bloomgarden Z
    J Diabetes; 2018 Mar; 10(3):186-187. PubMed ID: 29091343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c > 9.
    Weng J
    J Diabetes; 2017 Oct; 9(10):890-893. PubMed ID: 28661564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence of a threshold value of glycated hemoglobin to improve the course of renal function in type 2 diabetes with typical diabetic glomerulopathy.
    Brocco E; Velussi M; Cernigoi AM; Abaterusso C; Bruseghin M; Carraro A; Sambataro M; Piarulli F; Sfriso A; Nosadini R
    J Nephrol; 2001; 14(6):461-71. PubMed ID: 11783602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy.
    Lapolla A; Frison V; Bettio M; Dal Pos M; Rocchini P; Panebianco G; Tadiotto F; Da Tos V; D'Ambrosio M; Marangoni A; Ferrari M; Pianta A; Balzano S; Confortin L; Lamonica M; Marin N; Strazzabosco M; Brun E; Mesturino CA; Simoncini M; Zen F; Bax G; Bonsembiante B; Cardone C; Dal Frà MG; Gallo A; Masin M; Piarulli F; Sartore G; Simioni N
    Clin Ther; 2015 Mar; 37(3):574-84. PubMed ID: 25626486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of bromocriptine-QR on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral anti-diabetes agents.
    Vinik AI; Cincotta AH; Scranton RE; Bohannon N; Ezrokhi M; Gaziano JM
    Endocr Pract; 2012; 18(6):931-43. PubMed ID: 23186965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world Canagliflozin Utilization: Glycemic Control Among Patients With Type 2 Diabetes Mellitus-A Multi-Database Synthesis.
    Chow W; Miyasato G; Kokkotos FK; Bailey RA; Buysman EK; Henk HJ
    Clin Ther; 2016 Sep; 38(9):2071-82. PubMed ID: 27596020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
    Turner RC; Cull CA; Frighi V; Holman RR
    JAMA; 1999 Jun; 281(21):2005-12. PubMed ID: 10359389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial.
    Beck RW; Riddlesworth T; Ruedy K; Ahmann A; Bergenstal R; Haller S; Kollman C; Kruger D; McGill JB; Polonsky W; Toschi E; Wolpert H; Price D;
    JAMA; 2017 Jan; 317(4):371-378. PubMed ID: 28118453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Slow response to loss of glycemic control in type 2 diabetes mellitus.
    Brown JB; Nichols GA
    Am J Manag Care; 2003 Mar; 9(3):213-7. PubMed ID: 12643338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Individualized HbA
    Lautsch D; Boggs R; Wang T; Gonzalez C; Milligan G; Rajpathak S; Malkani S; McLeod E; Carroll J; Higgins V
    Adv Ther; 2022 Feb; 39(2):1016-1032. PubMed ID: 34951678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Starting insulin therapy in patients with type 2 diabetes: effectiveness, complications, and resource utilization.
    Hayward RA; Manning WG; Kaplan SH; Wagner EH; Greenfield S
    JAMA; 1997 Nov; 278(20):1663-9. PubMed ID: 9388085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of Flash Glucose Monitoring and Glycemic Control in Patients with Type 2 Diabetes Mellitus Not Treated with an Intensive Insulin Regimen: 1-Year Real-Life Retrospective Cohort Study.
    Al Hayek AA; Al Dawish MA
    Adv Ther; 2023 Jun; 40(6):2855-2868. PubMed ID: 37133646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensive structured self-monitoring of blood glucose and glycemic control in noninsulin-treated type 2 diabetes: the PRISMA randomized trial.
    Bosi E; Scavini M; Ceriello A; Cucinotta D; Tiengo A; Marino R; Bonizzoni E; Giorgino F;
    Diabetes Care; 2013 Oct; 36(10):2887-94. PubMed ID: 23735724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Greater Glycemic Burden Is Associated with Further Poorer Glycemic Control in Newly-Diagnosed Type 2 Diabetes Mellitus Patients.
    Wen WL; Huang HC; Lin HC; Lo WC; Chen SC; Lee MY
    Nutrients; 2022 Jan; 14(2):. PubMed ID: 35057503
    [No Abstract]   [Full Text] [Related]  

  • 16. Relative contributions of fasting and postprandial glucose increments, glycemic variability, and non-glycemic factors to HbA1c in individuals with type 1 diabetes.
    Zhou Y; Zheng M; Deng H; Zheng X; Luo S; Yang D; Mai X; Xu W; Yan J; Weng J
    J Diabetes; 2023 Jun; 15(6):465-473. PubMed ID: 37143431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Composite Glycemic Indices: A Comparison of the Comprehensive Glucose Pentagon Across Diabetes Types and HbA1c Levels.
    Rama Chandran S; A Vigersky R; Thomas A; Lim LL; Ratnasingam J; Tan A; S L Gardner D
    Diabetes Technol Ther; 2020 Feb; 22(2):103-111. PubMed ID: 31502876
    [No Abstract]   [Full Text] [Related]  

  • 18. Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia.
    Ross SA; Caballero AE; Del Prato S; Gallwitz B; Lewis-D'Agostino D; Bailes Z; Thiemann S; Patel S; Woerle HJ; von Eynatten M
    Postgrad Med; 2016 Nov; 128(8):747-754. PubMed ID: 27684308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial.
    Miser WF; Arakaki R; Jiang H; Scism-Bacon J; Anderson PW; Fahrbach JL
    Clin Ther; 2010 May; 32(5):896-908. PubMed ID: 20685497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM).
    Abraira C; Henderson WG; Colwell JA; Nuttall FQ; Comstock JP; Emanuele NV; Levin SR; Sawin CT; Silbert CK
    Diabetes Care; 1998 Apr; 21(4):574-9. PubMed ID: 9571345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.